Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2020

01-07-2020 | Breast Cancer | Preclinical study

Lipid biosignature of breast cancer tissues by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

Authors: Catarina L. Silva, Rosa Perestrelo, Ivo Sousa-Ferreira, Filipa Capelinha, José S. Câmara, Marijana Petković

Published in: Breast Cancer Research and Treatment | Issue 1/2020

Login to get access

Abstract

Purpose

One of the hallmarks of cancer cells is the demand of supply for the synthesis of new membranes involved in cell proliferation and lipids have an important role in cellular structure, signaling pathways and progression of cancer. In this sense, lipid studies have become an essential tool allowing the establishment of signatures associated with breast cancer (BC). In this regard, some metabolic processes including proteins, nucleic acids and lipid synthesis are enhanced as part of cancer-associated metabolic reprogramming, as a requirement for cell growth and proliferation.

Methods

Pairwise samples of breast active carcinoma (BAC) and breast cancer-free tissues were collected from n = 28 patients and analyzed by MALDI-TOF MS.

Results

Major lipid species are identified in the MALDI-TOF mass spectra, with certain phosphatidylinositols (PIs) detectable only in BAC. Statistical analysis revealed significant differences (p < 0.05) between ratios lysophosphatidylcholine (LPC) 16:0/phosphatidylcholine (PC) 16:0_18:2 between AC and CF groups as well as for BC stages II and III. The ratio PC 16:0_18:2/PC16:0_18:1 was statistically different between AC and CF groups. The one-way ANOVA revealed that there are no statistical differences among BC stages (I, II and III) within AC group. Comparing BC stages, the significance impact increased (p < 0.05) with stage.

Conclusion

The obtained data revealed MALDI-TOF MS as a powerful tool to explore lipid signatures and the enzyme activity associated with BC and possibly establish novel disease markers.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef
2.
Koek MM, Jellema RH, van der Greef J et al (2011) Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives. Metabolomics 7:307–328PubMedCrossRef
3.
Jelonek K, Ros M, Pietrowska M, Widlak P (2013) Cancer biomarkers and mass spectrometry-based analyses of phospholipids in body fluids. Clin Lipidol 8:137–150CrossRef
4.
Cho YT, Su H, Chiang YY et al (2017) Fine needle aspiration combined with matrix-assisted laser desorption ionization time-of-flight/mass spectrometry to characterize lipid biomarkers for diagnosing accuracy of breast cancer. Clin Breast Cancer 17:373–381.e1PubMedCrossRef
5.
Cho YT, Su H, Huang TL et al (2013) Matrix-assisted laser desorption ionization/time-of-flight mass spectrometry for clinical diagnosis. Clin Chim Acta 415:266–275PubMedCrossRef
6.
Islam SR, Manna SK (2019) Lipidomic analysis of cancer cell and tumor tissues. Methods Mol Biol 1928:175–204PubMedCrossRef
7.
Long J, Zhang C-J, Zhu N et al (2018) Lipid metabolism and carcinogenesis, cancer development. Am J Cancer Res 8:778–791PubMedPubMedCentral
8.
9.
Kim IC, Lee JH, Bang G et al (2013) Lipid profiles for HER2-positive breast cancer. Anticancer Res 33:2467–2472PubMed
10.
Fuchs B, Schiller J (2008) MALDI-TOF MS analysis of lipids from cells, tissues and body fluids. Subcell Biochem 49:541–565PubMedCrossRef
11.
Du Y, Wang Q, Zhang X et al (2017) Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma. J Exp Clin Cancer Res 36:66PubMedPubMedCentralCrossRef
12.
Abdelzaher E, Mostafa MF (2015) Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence. Tumor Biol 36:5473–5483CrossRef
13.
Uehara T, Kikuchi H, Miyazaki S et al (2016) Overexpression of lysophosphatidylcholine acyltransferase 1 and concomitant lipid alterations in gastric cancer. Ann Surg Oncol 23:206–213CrossRef
14.
Chen H-Z, Qu Y-H, Diao C-Y et al (2016) Expression of phospholipase A2 in breast cancer tissues and its significance. Int J Clin Exp Pathol 9(11):11820–11825
15.
Yamashita SI, Yamashita JI, Ogawa M (1994) Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69:1166–1170PubMedPubMedCentralCrossRef
16.
17.
Kim KJ, Kim HJ, Park HG et al (2016) A MALDI-MS-based quantitative analytical method for endogenous estrone in human breast cancer cells. Sci Rep 6:1–7CrossRef
18.
Phillips L, Gill AJ, Baxter RC (2019) Novel prognostic markers in triple-negative breast cancer discovered by MALDI-mass spectrometry imaging. Front Oncol 9:379PubMedPubMedCentralCrossRef
19.
Schiller J, Süß R, Arnhold J et al (2004) Matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) mass spectrometry in lipid and phospholipid research. Prog Lipid Res 43:449–488PubMedCrossRef
20.
Leopold J, Popkova Y, Engel K, Schiller J (2018) Recent developments of useful MALDI matrices for the mass spectrometric characterization of lipids. Biomolecules 8:173PubMedCentralCrossRef
21.
Fuchs B, Bischoff A, Sü R et al (2009) Phosphatidylcholines and -ethanolamines can be easily mistaken in phospholipid mixtures: a negative ion MALDI-TOF MS study with 9-aminoacridine as matrix and egg yolk as selected example. Anal Bioanal Chem 395:2479–2487PubMedCrossRef
22.
23.
Law S-H, Chan M-L, Marathe GK et al (2019) An updated review of lysophosphatidylcholine metabolism in human diseases. Int J Mol Sci 20:1149PubMedCentralCrossRef
24.
25.
Punnonen K, Hietanen E, Auvinen O, Punnonen R (1989) Phospholipids and fatty acids in breast cancer tissue. J Cancer Res Clin Oncol 115:575–578PubMedCrossRef
26.
Goto T, Terada N, Inoue T et al (2014) The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer. PLoS ONE 9:e90242PubMedPubMedCentralCrossRef
27.
Sparvero LJ, Amoscato AA, Dixon CE et al (2012) Mapping of phospholipids by MALDI imaging (MALDI-MSI): realities and expectations. Chem Phys Lipids 165:545–562PubMedPubMedCentralCrossRef
28.
Harvey DJ (1996) Matrix-assisted laser desorption/ionisation mass spectrometry of oligosaccharides and glycoconjugates. J Chromatogr A 720:429–446PubMedCrossRef
29.
Petković M, Schiller J, Müller M et al (2001) Detection of individual phospholipids in lipid mixtures by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: phosphatidylcholine prevents the detection of further species. Anal Biochem 289:202–216PubMedCrossRef
30.
Fuchs B, Süß R, Schiller J (2010) An update of MALDI-TOF mass spectrometry in lipid research. Prog Lipid Res 49:450–475PubMedCrossRef
31.
Petković M, Vocks A, Müller M et al (2005) Comparison of different procedures for the lipid extraction from HL-60 cells: A MALDI-TOF mass spectrometric study. Zeitschrift fur Naturforsch-Sect C J Biosci 60:143–151CrossRef
32.
Teuber K, Riemer T, Schiller J (2010) Thin-layer chromatography combined with MALDI-TOF-MS and 31P-NMR to study possible selective bindings of phospholipids to silica gel. Anal Bioanal Chem 398:2833–2842PubMedCrossRef
33.
Schiller J, Süß R, Fuchs B et al (2007) The suitability of different DHB isomers as matrices for the MALDI-TOF MS analysis of phospholipids: Which isomer for what purpose? Eur Biophys J 36:517–527PubMedCrossRef
34.
Schiller J, Süß R, Petković M, Arnold K (2002) Thermal stressing of unsaturated vegetable oils: Effects analysed by MALDI-TOF mass spectrometry,1H and31P NMR spectroscopy. Eur Food Res Technol 215:282–286CrossRef
35.
Schiller J, Arnhold J, Benard S et al (1999) Lipid analysis by matrix-assisted laser desorption and ionization mass spectrometry: a methodological approach. Anal Biochem 267:46–56PubMedCrossRef
36.
Angelini R, Vortmeier G, Corcelli A, Fuchs B (2014) A fast method for the determination of the PC/LPC ratio in intact serum by MALDI-TOF MS: An easy-to-follow lipid biomarker of inflammation. Chem Phys Lipids 183:169–175PubMedCrossRef
37.
Miletić Vukajlović J, Drakulić D, Pejić S et al (2019) Increased plasma phosphatidylcholine/lysophosphatidylcholine ratios in patients with Parkinson’s disease. Rapid Commun Mass Spectrom 34:8595
38.
Kamčeva T, Radisavljevic̈ M, Vukic̈evic̈ I, et al (2013) Interactions of platinum and ruthenium coordination complexes with pancreatic phospholipase A 2 and phospholipids investigated by MALDI TOF mass spectrometry. Chem Biodivers 10:1972–1986PubMedCrossRef
39.
Petković M, Müller J, Müller M et al (2002) Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring the digestion of phosphatidylcholine by pancreatic phospholipase A2. Anal Biochem 308:61–70PubMedCrossRef
40.
Kim Y, Shanta SR, Zhou LH, Kim KP (2010) Mass spectrometry based cellular phosphoinositides profiling and phospholipid analysis: A brief review. Exp Mol Med 42:1–11PubMedCrossRef
41.
Margaria JP, Ratto E, Gozzelino L et al (2019) Class II PI3Ks at the intersection between signal transduction and membrane trafficking. Biomolecules 9:104PubMedCentralCrossRef
42.
Dogliotti G, Kullmann L, Dhumale P et al (2017) Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression. Nat Commun 8:1–2CrossRef
43.
Müller M, Schiller J, Petković M et al (2001) Limits for the detection of (poly-)phosphoinositides by matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF MS). Chem Phys Lipids 110:151–164PubMedCrossRef
44.
Milne SB, Ivanova PT, DeCamp D et al (2005) A targeted mass spectrometric analysis of phosphatidylinositol phosphate species. J Lipid Res 46:1796–1802PubMedCrossRef
Metadata
Title
Lipid biosignature of breast cancer tissues by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
Authors
Catarina L. Silva
Rosa Perestrelo
Ivo Sousa-Ferreira
Filipa Capelinha
José S. Câmara
Marijana Petković
Publication date
01-07-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05672-9

Other articles of this Issue 1/2020

Breast Cancer Research and Treatment 1/2020 Go to the issue

Preclinical study

Androgen receptor expression inversely correlates with histological grade and N stage in ER+/PgRlow male breast cancer

Epidemiology

Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study

Letter to the Editor

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy

Clinical Trial

Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age

Letter to the Editor

Fertility and reproduction in breast cancer patients

Epidemiology

Association between thyroid gland diseases and breast cancer: a case–control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits